Cardiac amyloidosis - Sustained clinical and free light chain response to low dose thalidomide and corticosteroids [2]

Internal Medicine Journal

Volumn 36, Issue 2, 2006, Pages 137-139

  Campbell, P ^a   Murdock, C ^a  

^a GEELONG HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; FUROSEMIDE; IMMUNOGLOBULIN LIGHT CHAIN; PREDNISOLONE; SPIRONOLACTONE; THALIDOMIDE;

ADULT; ANAMNESIS; BRAIN CONTUSION; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEART AMYLOIDOSIS; HEART FAILURE; HEART MUSCLE BIOPSY; HUMAN; HUMAN TISSUE; LETTER; MAINTENANCE THERAPY; MALE; PRIORITY JOURNAL; PROGNOSIS; SKULL FRACTURE; SYNCOPE; THROMBOSIS;

AMYLOIDOSIS; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEART DISEASES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 33344468728     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.01021.x     Document Type: Letter

References (8)

1. Bird J, Cavenagh J, Hawkins P, Lachmann H, Mehta A, Samson D. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 2004; 125: 681-700.
2. Lachmann HJ, Gallimore R, Gillimore JD, Carr-Smith HD, Bradwell AR, Pepys MB et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003; 122: 78-84.
3. Bakshi NA, Gulbranson R, Gartska D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing proteins. Am J Clin Pathol 2005; 124: 214-8.
4. Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949-51.
5. Dispenzieri A, Lacy MQ, Rajkumar SV, Geyer SM, Fonseca R, Witzig TE et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257-61.
6. Seldin DC, Choufani EB, Dember LM, Wiesman JF, Berk JL, Falk RH et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3: 241-6.
7. Goodman HJB, Lachmann HJ, Gallimore R, Bradwell AR, Hawkins PN. Thalidomide treatment in 99 patients with AL amyloidosis: tolerability, clonal disease response and clinical outcome. Haematologica 2005; 90: 202a.
8. Palladini G, Anesi E, Perfetti V, Obici L, Invernizzi R, Balduini C et al. A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 2001; 113: 1044-6.